ATLAS: Adjuvant Tamoxifen Longer Against Shorter
Abstract
ATLAS an international trial designed to assess the optimal duration of adjuvant tamoxifen - received its original funding by the U.S. Army in 1995. Following the approval of the final report, a further year's funding was awarded. The current report covers the work done with the additional funding. ATLAS remains on course to achieve its overall objectives. More than 400 hospitals have ethics approval, and more than 300 centers are randomizing women into the trial. With the implementation of the ATLAS Patient Identification and Registration Project, ATLAS has systematically identified more than 7000 women who are currently on tamoxifen and who are eligible for entry either now or at some time in the future to ATLAS - the registration target is 30,000, which will be reached during the next 2-3 years. At 06/2000, more than 6000 women have been randomized - ATLAS should reach its accrual target in 2005. Follow-up will continue at least until 2010, when the main results of the trial will be reported. The ATLAS Oestrogen Receptor Detection Project is now being implemented to ensure that the ER status of all randomized women in ATLAS is ascertained. The independent Data Monitoring Committee for ATLAS convened in June 1999, when it endorsed the continuing importance of ATLAS and confirmed that the trial was progressing satisfactorily. For ATLAS to achieve its main objectives, additional funding is required and is requested as part of this report.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2000
- Accession Number
- ADA391788
Entities
People
- Richard Peto
Organizations
- University of Oxford